Answers are grounded in this paper and cite their sources.
Tiotropium resulted in a higher FEV₁ than placebo at 24 months and ameliorated the annual decline in the FEV₁ after bronchodilator use in patients with COPD of GOLD stage 1 or 2. (Funded by Boehringer Ingelheim and others; Tie-COPD ClinicalTrials.gov number, NCT01455129 .).
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: